EurekaMag.com logo
+ Site Statistics
References:
52,725,316
Abstracts:
28,411,598
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Trh counteracts neuronal damage induced by a substance p antagonist


Experimental Brain Research 62(1): 175-178
Trh counteracts neuronal damage induced by a substance p antagonist
Intrathecal administration of the substance P antagonist Spantide caused marked necrotic changes of the gray matter of the spinal cord extending several segments from the injection site. Intravenous treatment with several doses of thyrotropin releasing hormone before and after Spantide injection completely prevented the necrotic lesion.


Accession: 006839704



Related references

Thyrotropin-releasing hormone (TRH) counteracts neuronal damage induced by a substance P antagonist. Experimental Brain Research 62(1): 175-178, 1986

Gc-protein-derived macrophage activating factor counteracts the neuronal damage induced by oxaliplatin. Anti-Cancer Drugs 26(2): 197-209, 2015

Ferulic Acid Regulates the Nrf2/Heme Oxygenase-1 System and Counteracts Trimethyltin-Induced Neuronal Damage in the Human Neuroblastoma Cell Line SH-SY5Y. Frontiers in Pharmacology 6: 305-305, 2016

Hypoglycemia-induced neuronal damage prevented by an N-methyl-D-aspartate antagonist. Science 230(4726): 681-683, 1985

Effects of non-NMDA receptor antagonist against in vivo hypoxia-induced neuronal damage. Japanese Journal of Pharmacology 71(SUPPL 1): 283P, 1996

Substance P counteracts neurotoxin damage on norepinephrine neurons in rat brain during ontogeny. Science 215(4528): 75-77, 1982

The NK-1 Receptor Antagonist L-732,138 Induces Apoptosis and Counteracts Substance P-Related Mitogenesis in Human Melanoma Cell Lines. Cancers 2(2): 611-623, 2010

The competitive NMDA receptor antagonist CGP 40116 protects against status epilepticus-induced neuronal damage. Epilepsy Research 17(3): 207-219, 1994

The competitive NMDA receptor antagonist CGP 40116 protects against status epilepticus-induced neuronal damage. Epilepsy Research 17(3): 207-219, 1994

The non-NMDA glutamate receptor antagonist GYKI 52466 counteracts locomotor stimulation and anticataleptic activity induced by the NMDA antagonist dizocilpine. Naunyn-Schmiedeberg's Archives of Pharmacology 348(5): 486-490, 1993